These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21521267)

  • 1. Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues.
    Tzanela M; Vassiliadi DA; Gavalas N; Szabo A; Margelou E; Valatsou A; Vassilopoulos C
    Clin Endocrinol (Oxf); 2011 Jul; 75(1):96-102. PubMed ID: 21521267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of medical therapies for acromegaly on glucose metabolism.
    Urbani C; Sardella C; Calevro A; Rossi G; Scattina I; Lombardi M; Lupi I; Manetti L; Martino E; Bogazzi F
    Eur J Endocrinol; 2013 Jul; 169(1):99-108. PubMed ID: 23660641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors.
    Ronchi CL; Varca V; Beck-Peccoz P; Orsi E; Donadio F; Baccarelli A; Giavoli C; Ferrante E; Lania A; Spada A; Arosio M
    J Clin Endocrinol Metab; 2006 Jan; 91(1):121-8. PubMed ID: 16263816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly.
    Steffin B; Gutt B; Bidlingmaier M; Dieterle C; Oltmann F; Schopohl J
    Eur J Endocrinol; 2006 Jul; 155(1):73-8. PubMed ID: 16793952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment.
    Baldelli R; Battista C; Leonetti F; Ghiggi MR; Ribaudo MC; Paoloni A; D'Amico E; Ferretti E; Baratta R; Liuzzi A; Trischitta V; Tamburrano G
    Clin Endocrinol (Oxf); 2003 Oct; 59(4):492-9. PubMed ID: 14510913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study.
    Colao A; Auriemma RS; Galdiero M; Cappabianca P; Cavallo LM; Esposito F; Grasso LF; Lombardi G; Pivonello R
    J Clin Endocrinol Metab; 2009 Feb; 94(2):528-37. PubMed ID: 19001517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy.
    Colao A; Pivonello R; Galderisi M; Cappabianca P; Auriemma RS; Galdiero M; Cavallo LM; Esposito F; Lombardi G
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2639-46. PubMed ID: 18445662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response.
    Helseth R; Carlsen SM; Bollerslev J; Svartberg J; Øksnes M; Skeie S; Fougner SL
    Endocrine; 2016 Feb; 51(2):298-307. PubMed ID: 26179177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues.
    Ronchi CL; Orsi E; Giavoli C; Cappiello V; Epaminonda P; Beck-Peccoz P; Arosio M
    J Endocrinol Invest; 2003 Jun; 26(6):533-8. PubMed ID: 12952367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA.
    De Marinis L; Bianchi A; Fusco A; Cimino V; Mormando M; Tilaro L; Mazziotti G; Pontecorvi A; Giustina A
    Pituitary; 2007; 10(3):227-32. PubMed ID: 17484056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
    Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of long-acting release octreotide on glucose homeostasis in acromegaly patients after trans-sphenoidal surgery.
    Chen HS; Wu TE; Jap TS; Hsiao LC; Lin HD; Lee SH; Lin SH
    Horm Metab Res; 2011 Jun; 43(6):433-9. PubMed ID: 21538290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The metabolic profile in active acromegaly is gender-specific.
    Ciresi A; Amato MC; Pivonello R; Nazzari E; Grasso LF; Minuto F; Ferone D; Colao A; Giordano C
    J Clin Endocrinol Metab; 2013 Jan; 98(1):E51-9. PubMed ID: 23162101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study.
    Giordano C; Ciresi A; Amato MC; Pivonello R; Auriemma RS; Grasso LF; Galluzzo A; Colao A
    Pituitary; 2012 Dec; 15(4):539-51. PubMed ID: 22116639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies.
    Mazziotti G; Floriani I; Bonadonna S; Torri V; Chanson P; Giustina A
    J Clin Endocrinol Metab; 2009 May; 94(5):1500-8. PubMed ID: 19208728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events associated with somatostatin analogs in acromegaly.
    Grasso LF; Auriemma RS; Pivonello R; Colao A
    Expert Opin Drug Saf; 2015 Aug; 14(8):1213-26. PubMed ID: 26184380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory adipokines contribute to insulin resistance in active acromegaly and respond differently to different treatment modalities.
    Olarescu NC; Ueland T; Godang K; Lindberg-Larsen R; Jørgensen JO; Bollerslev J
    Eur J Endocrinol; 2014 Jan; 170(1):39-48. PubMed ID: 24092547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly.
    Gatto F; Biermasz NR; Feelders RA; Kros JM; Dogan F; van der Lely AJ; Neggers SJ; Lamberts SW; Pereira AM; Ferone D; Hofland LJ
    Eur J Endocrinol; 2016 May; 174(5):651-62. PubMed ID: 26888629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
    Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.